]
October 27, 2022

WHO’s new TB numbers highlight an emergency in need of action

Statement from Mel Spigelman, MD, President and CEO, TB Alliance
September 19, 2022

TB Alliance Board of Directors Appoints Two New Members

Kim Schwartz and Rasha Hibri are Welcomed to the Board
August 31, 2022

Drug-Resistant TB Trial Results Published in New England Journal of Medicine

Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of Linezolid
August 17, 2022

PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials

Public-private collaboration to evaluate five antimicrobial agents across two combination regimens for treating both drug-susceptible and drug-resistant forms of TB with shorter treatment durations
June 1, 2022

TB Alliance Names Pietro Turilli as Head of External Affairs

Executive brings more than 20 years in global partnerships and resource mobilization

Pages